We hypothesize that NPM1 may be similarly interacting with Aβ aggregates in AD, potentially explaining the observed correlation: higher NPM1 levels could be associated with lower Aβ aggregation, reduced AD pathology and greater preservation of brain volume. Here, NPM1 is linked to Alzheimer disease.